No licensed vaccine exists to stop it, and no specific treatment to cure it.
Along the borders of East and Central Africa, where the movement of people has always outpaced the drawing of lines on maps, a rare strain of Ebola called Bundibugyo is testing the region's capacity for collective vigilance. With 121 confirmed cases and hundreds of suspected deaths spanning the Democratic Republic of Congo and Uganda, health ministers of the East African Community gathered virtually on June 1 and 2 to forge a unified response to an outbreak that carries an added weight of uncertainty — no licensed vaccine exists, and no specific cure. The meeting is both a practical coordination and a moral reckoning with how nations choose to protect one another when the threat is shared.
- A rare Bundibugyo Ebola strain — one for which no vaccine or treatment exists — has claimed at least 17 confirmed deaths in DR Congo and is spreading through Ituri Province, with Uganda already recording its first confirmed cases.
- The gap between confirmed and suspected figures is alarming: 121 confirmed cases sit alongside 1,077 suspected cases and 246 suspected deaths, suggesting the true scale of the outbreak may be far larger than official tallies reflect.
- Borders are proving to be no barrier — Uganda's first two patients traveled from Congo seeking care, forcing the entire region to treat this as a shared crisis rather than a bilateral one.
- Nine mobile laboratories are being rushed to border crossings and high-risk sites across seven countries, while over 180 emergency responders stand ready to deploy and 500 PPE sets have already been distributed to frontline workers.
- Governments are racing to build a regional fast-track mechanism for approving Ebola vaccines and therapeutics, compressing bureaucratic timelines in hopes of outpacing the virus's spread.
On June 1 and 2, East African Community health ministers convened by video to coordinate a regional response to a Bundibugyo Ebola outbreak moving through the Democratic Republic of Congo and Uganda. The Bundibugyo strain is rare enough that no licensed vaccine or specific treatment exists — a fact that sharpens the urgency of every decision being made.
The outbreak was confirmed on May 15. By late May, DR Congo had recorded 121 confirmed cases and 17 confirmed deaths, alongside 1,077 suspected cases and 246 deaths among them. Uganda had documented seven confirmed cases and one death. The first Ugandan patients had crossed from Congo seeking treatment, a quiet illustration of how porous borders are when disease is moving. Ituri Province in eastern Congo has been identified as the epicenter, with North Kivu and South Kivu also affected.
The EAC's response is already in motion. Nine mobile laboratories are being deployed to border crossings and high-risk locations across the region — including Rwanda, Kenya, South Sudan, Burundi, Tanzania, Uganda, and Congo itself. The Uganda Virus Research Institute is providing laboratory support and specialized training. Health workers are being trained through the EAC's TEACH program, and more than 180 emergency responders from the organization's Rapidly Deployable Expert Pool are on standby. Five hundred sets of personal protective equipment have been procured for Congo and Uganda, with more on the way.
Running alongside the operational response is a longer-term effort: establishing a regional mechanism to accelerate the approval of Ebola vaccines, therapeutics, and diagnostics. The June meeting is where these threads are being pulled together — where gaps are named, directives sharpened, and the region's collective resolve is measured against a pathogen that, for now, has no pharmaceutical answer.
On June 1 and 2, health ministers from across the East African Community will convene by video to map out a unified strategy against an Ebola outbreak spreading through the Democratic Republic of Congo and Uganda. The virus in question is the Bundibugyo strain—uncommon enough that no licensed vaccine exists to stop it, and no specific treatment to cure it. The stakes are regional, and the clock is moving.
The outbreak was officially confirmed on May 15. By late May, the numbers had begun to accumulate with grim precision. The Democratic Republic of Congo reported 121 confirmed cases, with 17 deaths among those confirmed. But the confirmed cases were only part of the picture. The country had also logged 1,077 suspected cases, and among those suspected cases, 246 people had died. Uganda, meanwhile, had documented seven confirmed cases and one death as of May 25. The first two Ugandan patients had traveled from the Congo seeking treatment, a reminder that borders are porous and disease does not recognize them.
Ituri Province in eastern Congo has emerged as the epicenter, though the outbreak has also touched North Kivu and South Kivu. Health authorities are treating Ituri as the fire's hottest point, the place where containment matters most.
The East African Community is not waiting passively. Stephen Mbundi, the EAC Secretary General, framed the response as a coordinated mobilization across the entire bloc. The organization is working with the Africa CDC, the World Health Organization, and development partners to shore up surveillance systems, improve laboratory diagnosis, strengthen infection control protocols, and build rapid-response capacity. The goal is explicit: prevent the virus from crossing borders while preserving the health, economic stability, and social fabric of East Africa.
The practical machinery is already moving. Nine mobile laboratories are being deployed to strategic border points and high-risk locations across the region. In Rwanda, two of these will be stationed at Gisenyi and Gihundwe hospitals in the border districts of Rubavu and Rusizi. Others are headed to the Congo, Kenya, South Sudan, Burundi, Tanzania, and Uganda. These labs will enable rapid testing and surveillance of the Bundibugyo virus. The Uganda Virus Research Institute, which functions as the EAC's regional center of excellence on virology, is providing laboratory support and specialized training.
Beyond the labs, the EAC is training health workers through its TEACH program, which specializes in managing high-consequence infectious diseases. Additional training is being planned for emergency medical teams and health experts from countries deemed at higher risk of cross-border transmission. The organization has also activated its Rapidly Deployable Expert Pool—a roster of more than 180 emergency responders stationed across East Africa, ready to move. To equip frontline workers, the EAC has procured 500 sets of personal protective equipment for the Congo and Uganda, with more supplies in the pipeline for other member states.
Parallel discussions are underway to establish a regional mechanism for the accelerated approval and registration of Ebola vaccines, therapeutics, and diagnostics. This is not bureaucratic theater. It is an attempt to compress the timeline between a drug's development and its deployment, to move faster than the virus spreads.
The EAC has issued a call to all member states: strengthen surveillance at points of entry, enhance cross-border coordination, activate emergency preparedness plans, and ramp up public awareness. The meeting on June 1 and 2 will be where those directives are refined, where gaps are identified, and where the region's collective will is tested against a pathogen that has no vaccine and no cure.
Citações Notáveis
We are mobilising regional mechanisms and working closely with partner states, Africa CDC, WHO and development partners to strengthen surveillance, laboratory diagnosis, infection prevention and control, risk communication, and rapid response capacities.— Stephen Mbundi, EAC Secretary General
A Conversa do Hearth Outra perspectiva sobre a história
Why does the fact that there's no vaccine matter so much here? Aren't there other ways to stop an outbreak?
A vaccine would let you protect people before they're exposed. Without one, you're entirely dependent on finding cases fast, isolating them, and preventing contact. It's reactive instead of preventive. That's why the mobile labs matter so much—they're trying to catch cases at the border before they spread deeper into the region.
The Bundibugyo strain is described as rare. Does that mean it's less dangerous than other Ebola strains?
Rare doesn't mean less dangerous. It means we have less experience with it, less data on how it spreads, less institutional knowledge about what works. That uncertainty is part of what makes this urgent. The health systems in the region have to learn as they go.
Why is Ituri Province the epicenter? What makes it different?
The source doesn't say explicitly, but Ituri is in eastern Congo—a region with dense population, weak health infrastructure, and a history of conflict. Those conditions tend to amplify outbreaks. Once a virus takes hold in a place like that, it moves fast.
The EAC is deploying 180 emergency responders. That sounds like a lot. Is it enough?
It's what they have mobilized. Whether it's enough depends on how fast the outbreak spreads and where. The real test is whether those responders can get to new cases before the virus does.
What does it mean that they're establishing a regional mechanism for accelerated vaccine approval?
Normally, a vaccine goes through months or years of regulatory review in each country. They're trying to create a fast track—one approval process for the whole region instead of seven separate ones. It saves time, but it also requires trust between countries that their standards are compatible.
If Uganda only has seven confirmed cases, why is the EAC mobilizing this heavily?
Because seven confirmed cases today can become seventy in a week. The virus is already across the border. The question isn't whether Uganda will have more cases—it's whether the region can contain it before it becomes a continental crisis.